282 related articles for article (PubMed ID: 30359639)
1. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H
Riddy DM; Cook AE; Shackleford DM; Pierce TL; Mocaer E; Mannoury la Cour C; Sors A; Charman WN; Summers RJ; Sexton PM; Christopoulos A; Langmead CJ
Neuropharmacology; 2019 Jan; 144():244-255. PubMed ID: 30359639
[TBL] [Abstract][Full Text] [Related]
2. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
3. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
4. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
Sadek B; Schwed JS; Subramanian D; Weizel L; Walter M; Adem A; Stark H
Eur J Med Chem; 2014 Apr; 77():269-79. PubMed ID: 24650714
[TBL] [Abstract][Full Text] [Related]
5. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.
Sors A; Panayi F; Bert L; Favale D; Nosjean O; Audinot V; Arrang JM; Buisson B; Steidl E; Delbos JM; Huhtala T; Kontkanen O; Chollet AM; Casara P; Lestage P
Eur J Pharmacol; 2017 May; 803():11-23. PubMed ID: 28336400
[TBL] [Abstract][Full Text] [Related]
7. Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs.
Lipani L; Odadzic D; Weizel L; Schwed JS; Sadek B; Stark H
Eur J Med Chem; 2014 Oct; 86():578-88. PubMed ID: 25218907
[TBL] [Abstract][Full Text] [Related]
8. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.
Provensi G; Costa A; Passani MB; Blandina P
Neuropharmacology; 2016 Oct; 109():139-147. PubMed ID: 27291828
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon.
Logan J; Carruthers NI; Letavic MA; Sands S; Jiang X; Shea C; Muench L; Xu Y; Carter P; King P; Fowler JS
Psychopharmacology (Berl); 2012 Oct; 223(4):447-55. PubMed ID: 22614669
[TBL] [Abstract][Full Text] [Related]
10. 4-Hydroxypiperidines and Their Flexible 3-(Amino)propyloxy Analogues as Non-Imidazole Histamine H₃ Receptor Antagonist: Further Structure⁻Activity Relationship Exploration and In Vitro and In Vivo Pharmacological Evaluation.
Olszewska B; Stasiak A; McNaught Flores D; Fogel WA; Leurs R; Walczyński K
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671795
[TBL] [Abstract][Full Text] [Related]
11. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
12. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L
ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
Zeng Q; Rosenblum SB; Yang Z; Jiang Y; McCormick KD; Aslanian RG; Duguma L; Kozlowski JA; Shih NY; Hey JA; West RE; Korfmacher WA; Berlin M; Boyce CW
Bioorg Med Chem Lett; 2013 Nov; 23(21):6001-3. PubMed ID: 24050887
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Esbenshade TA; Browman KE; Miller TR; Krueger KM; Komater-Roderwald V; Zhang M; Fox GB; Rueter L; Robb HM; Radek RJ; Drescher KU; Fey TA; Bitner RS; Marsh K; Polakowski JS; Zhao C; Cowart MD; Hancock AA; Sullivan JP; Brioni JD
J Pharmacol Exp Ther; 2012 Oct; 343(1):233-45. PubMed ID: 22815533
[TBL] [Abstract][Full Text] [Related]
16. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
17. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Brackenborough K; Briggs MA; Brough S; Calver AR; Crook B; Davis RK; Davis RP; Davis S; Dean DK; Harris L; Heslop T; Holland V; Jeffrey P; Panchal TA; Parr CA; Quashie N; Schogger J; Sehmi SS; Stean TO; Steadman JG; Trail B; Wald J; Worby A; Takle AK; Witherington J; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6890-6. PubMed ID: 24269482
[TBL] [Abstract][Full Text] [Related]
18. The naturally occurring mutation Y197C does not affect the expression or signaling of the human histamine H
Flores-Clemente C; Escamilla-Sánchez J; Arias JM; Arias-Montaño JA
Neurosci Lett; 2017 Feb; 641():77-80. PubMed ID: 28126588
[TBL] [Abstract][Full Text] [Related]
19. Histamine H
Ghamari N; Zarei O; Arias-Montaño JA; Reiner D; Dastmalchi S; Stark H; Hamzeh-Mivehroud M
Pharmacol Ther; 2019 Aug; 200():69-84. PubMed ID: 31028835
[TBL] [Abstract][Full Text] [Related]
20. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
